Methods for treating or preventing asthma by administering an il-4r antagonist
AssigneesSanofi Biotechnology, Regeneron Pharmaceuticals, Inc.
InventorsGianluca Pirozzi, Franck Skobieranda, Yongtao Li, Neil Graham, Steven P. Weinstein
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Claims13
1-314. (canceled)
A method for treating moderate to severe asthma in a subject on a background therapy comprising an inhaled corticosteroid (ICS), comprising
- subcutaneously administering to the subject an initial dose of 600 mg of dupilumab followed by one or more secondary doses every other week (q2w) of 300 mg of the dupilumab,
- wherein the dupilumab is administered as an add-on maintenance treatment, and
- wherein the subject has a blood eosinophil count of greater than or equal to 300 cells/μL and a fractional exhaled NO (FeNO) level of more than about 35 ppb at baseline.
A method for treating moderate to severe asthma in a subject on a background therapy comprising an inhaled corticosteroid (ICS), comprising
- subcutaneously administering to the subject an initial dose of 400 mg of dupilumab followed by one or more secondary doses every other week (q2w) of 200 mg of the dupilumab,
- wherein the dupilumab is administered as an add-on maintenance treatment, and
- wherein the subject has a blood eosinophil count of greater than or equal to 300 cells/μL and a fractional exhaled NO (FeNO) level of more than about 35 ppb at baseline.
Dependencies are inferred from the claim text.